4507   Shionogi & Co.,Ltd.

06/01/2020 09:35	Notice Regarding a New Medium-Term Business Plan
06/01/2020 09:30	2030 Vision and New Medium-Term Business Plan
05/26/2020 13:00	Notice Regarding Tetra becoming a wholly owned subsidiary of Shionogi
05/25/2020 08:00	Items Disclosed on internet Concerning Notice of Convacation Annual General Meeting 2020
05/25/2020 08:00	Notice of Convacation Annual General Meeting 2020
05/12/2020 08:30	FY2019 Financial Results
05/11/2020 13:00	Financial Results for Fiscal Year 2019 (Consolidated)
05/11/2020 13:00	Financial Results for the year ended March 31,2020
05/11/2020 13:00	FY2019 Financial Results(April 2019-march 2020)
04/28/2020 09:00	SHIONOGI RECEIVES EUROPEAN COMMISSION MARKETING AUTHORISATION FOR FETCROJA(R)(CEFIDEROCOL)
04/27/2020 15:00	Notice Regarding a Development Decision of Vaccine for COVID-19
04/24/2020 13:00	Notice of Revisions to Dividend Forecasts (Divident Increase)
04/22/2020 15:00	Position and Policy Regarding Reduction of the Investment Unit
04/07/2020 12:00	Notice Regarding Completion of Cancellation of Treasury Shares(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Compan
03/31/2020 15:00	Shionogi Filed for the Supplemental New Drug Application of Xofluza(R) in Taiwan for the Post-Exposure Prophylaxis of Influenza Virus Infection
03/30/2020 15:10	Notice Regarding the Signing of the Basic Agreement with Ping An Insurance for a Capital and Business Alliance including the Disposal of Treasury Shar
03/30/2020 15:10	Notice Regarding Changes of Cancellation of Treasury Shares
03/27/2020 15:00	FDA Accepts a New Drug Application for a New Formulation and Two Supplemental New Drug Applications for XOFLUZA(R) (Baloxavir Marboxil)
03/19/2020 08:30	presentation material of R&D meeting of FY2019
03/17/2020 11:30	Business Partnership with Micro Blood Science Inc. for an IgG/IgM Antibody-test Kit for COVID-19
03/09/2020 15:00	Notice Regarding the Status and Completion of Acquisition of Own Shares
03/06/2020 11:30	Shionogi and Tetra Therapeutics Entered into New Strategic Collaboration for BPN14770
03/03/2020 09:00	SHIONOGI RECEIVES POSITIVE CHMP OPINION FOR FETCROJA(R) (CEFIDEROCOL)
02/07/2020 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
02/03/2020 13:00	3rd Quarter of Fiscal 2019 Financial Results Conference Call
02/03/2020 13:00	Financial Results for the Third Quarter of Fiscal Year 2019
02/03/2020 13:00	Financial Results for the Third Quarter of Fiscal Year 2019 (Consolidated)
01/08/2020 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
12/13/2019 15:00	Shionogi Announces Results of Tender Offer for Certificate of Shares, Etc. in UMN Pharma Inc. (Securities Code: 4585) and Changes in a Subsidiary
12/04/2019 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
11/25/2019 15:00	Shionogi Announces XOFLUZA(R) Tablets 20mg for the Treatment of Influenza A or B virus Acute Infection Launched in Taiwan.
11/22/2019 15:00	[Delayed] Amendments: In Association with Its Submission of an Amendment of Tender Offer Statement, Shionogi Announces
11/15/2019 15:00	FETROJA(R) (cefiderocol) Approved by the FDA for Treatment ofComplicated Urinary Tract Infections (cUTI) in Adult Patients
11/01/2019 16:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
10/31/2019 09:00	1st Half of Fiscal 2019 Financial Results
10/30/2019 18:40	Shionogi Announces Commencement of Tender Offer for Certificates of Shares, Etc. in UMN Pharma Inc.(Securities Code: 8840)
10/30/2019 13:00	1st Half of Fiscal 2019 Financial Results
10/30/2019 13:00	Financial Results for the Second Quarter of Fiscal Year 2019(Consolidated)
10/28/2019 15:00	Update on the Japanese Association for Infectious Diseases Statement and Revised Guidelines of the Japanese Pediatric Society for the Treatment of Flu
10/18/2019 15:00	FDA Approves XOFLUZA(TM) for the Treatment of Acute Uncomplicated Influenza for People at High Risk of Developing Influenza-Related Complications
10/17/2019 10:00	U.S. FDA Advisory Committee Recommends Approval of Cefiderocol for Treatment of Complicated Urinary Tract Infections
10/16/2019 15:00	Shionogi Filed for the Supplemental New Drug Application of XOFLUZA(R) in Japan for the Post-Exposure Prophylaxis of Influenza Virus Infection
10/03/2019 09:00	Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens
10/02/2019 11:30	Congress Presentation on Clinical Study of S-600918, a Drug Candidate for the Treatment of Refractory/Unexplained Chronic Cough
09/30/2019 13:00	Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares
09/02/2019 15:00	Special Drug Use Survey for XOFLUZA(R) Announced at OPTIONS X
09/02/2019 15:00	The Results of Analyses of PA/I38X-substituted Viruses in XOFLUZA(R) Clinical Studies
09/02/2019 15:00	Positive Results for XOFLUZATM Global Phase III Study (MINISTONE-2)in Children with Influenza
09/02/2019 15:00	Shionogi Announces Post-Exposure Prophylaxis Results for XOFLUZA(R) in PhaseIII Study (BLOCKSTONE) of Influenza Virus Infection in Household Members
08/29/2019 11:30	Shionogi Announces XOFLUZA Tablets 20mg for The Treatment of Influenza Types A and B in Patients 12 years of Age and older Approved in Taiwan.
07/29/2019 13:00	Financial Results for the First Quarter of Fiscal Year 2019 (Consolidated)
07/29/2019 13:00	Financial Results for the First Quarter of Fiscal Year 2019
07/29/2019 13:00	1st Quarter of Fiscal 2019 Financial Results Conference Call
07/22/2019 16:10	Shionogi announces out-licensing agreement with AMR Centre on COT-143,a humanized monoclonal antibody targeting the PcrV protein of P. aeruginosa
07/19/2019 09:00	Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
07/01/2019 15:00	Corporate Governance Report 2019
06/24/2019 11:00	Shionogi Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lusutrombopag, a Thrombopoietin Receptor Agonist and Epertinib, an HER2/EG
06/19/2019 15:15	SHIONOGI AND FERRER CONCLUDE A CONTRACT FOR THE PROMOTION IN SPAIN OF RIZMOIC(R) (NALDEMEDINE), A THERAPEUTIC AGENT FOR OPIOID-INDUCED CONSTIPATION
06/18/2019 17:00	Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
06/18/2019 17:00	Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019
06/13/2019 14:00	Shionogi Purchases All Outstanding Shares of Pionnier following the Conclusion of their Joint Study
06/04/2019 15:00	Shionogi Announces Positive Top-Line Results for XOFLUZA(R) (Baloxavir Marboxil) Phase III Study (BLOCKSTONE)